Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia

Herein, we present the final report of a single-center, prospective phase II study evaluating ibrutinib 420 mg once daily in 30 treatment-naive patients with Waldenstrom macroglobulinemia (WM). The present study is registered with ClinicalTrials.Gov (NCT02604511). With a median follow-up of 50 month...

Full description

Bibliographic Details
Main Authors:	Branagan, A.R (Author), Castillo, J.J (Author), Demos, M.G (Author), Flynn, C.A (Author), Guerrera, M.L (Author), Gustine, J.N (Author), Hunter, Z.R (Author), Kofides, A. (Author), Leventoff, C. (Author), Liu, X. (Author), Meid, K. (Author), Munshi, M. (Author), O’Donnell, E. (Author), Patterson, C.J (Author), Raje, N. (Author), Sarosiek, S. (Author), Treon, S.P (Author), Tsakmaklis, N. (Author), White, T. (Author), Xu, L. (Author), Yang, G. (Author), Yee, A.J (Author)
Format:	Article
Language:	English
Published:	Springer Nature 2022
Subjects:	adenine Adenine adult Adult aged Aged Aged, 80 and over female Female follow up Follow-Up Studies human Humans ibrutinib male Male middle aged Middle Aged pathology piperidine derivative Piperidines prognosis Prognosis Prospective Studies prospective study survival rate Survival Rate very elderly Waldenstroem macroglobulinemia Waldenstrom Macroglobulinemia
Online Access:	View Fulltext in Publisher

Internet

View Fulltext in Publisher

Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia

Internet

Similar Items